-
1.发明授权公开(公告)号：US12097242B2
公开(公告)日：2024-09-24
申请号：US17721569
申请日：2022-04-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
CPC classification number: A61K38/18 , A61K38/2221 , C07K1/1077 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20230295346A1
公开(公告)日：2023-09-21
申请号：US18180998
申请日：2023-03-09
Applicant: BRISTOL -MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, JR. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
IPC: C07K16/46 , A61K39/395 , A61K47/60 , A61K47/65 , C07K16/28
CPC classification number: C07K16/464 , A61K39/39533 , A61K47/60 , A61K47/65 , C07K16/2818 , C07K16/2878 , A61P29/00 , C07K2317/24 , C07K2317/515 , C07K2317/76 , C07K2319/50
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
公开(公告)号：US11364281B2
公开(公告)日：2022-06-21
申请号：US17198939
申请日：2021-03-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US12097241B2
公开(公告)日：2024-09-24
申请号：US17573238
申请日：2022-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
CPC classification number: A61K38/18 , A61K38/2221 , C07K1/1077 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US11623965B2
公开(公告)日：2023-04-11
申请号：US16103654
申请日：2018-08-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, Jr. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
Patent Agency Ranking
公开(公告)号：US20220211812A1
公开(公告)日：2022-07-07
申请号：US17573238
申请日：2022-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20210196791A1
公开(公告)日：2021-07-01
申请号：US17198939
申请日：2021-03-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US10266578B2
公开(公告)日：2019-04-23
申请号：US15891492
申请日：2018-02-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US09631004B2
公开(公告)日：2017-04-25
申请号：US15215329
申请日：2016-07-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
CPC classification number: A61K38/1825 , A61K38/00 , A61K45/06 , A61K47/60 , A61K47/64 , C07K14/50 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
10.发明授权公开(公告)号：US12247058B2
公开(公告)日：2025-03-11
申请号：US17555633
申请日：2021-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Nucleic acids encoding modified FGF-21 polypeptides, optionally containing at least one non-codon encoding a naturally-encoded amino acid, and vectors and cells containing are provided. These nucleic acids can be used to express the modified FGF-21 polypeptide encoded thereby. The expressed FGF-21 polypeptides may be used as therapeutics, e.g., in the treatment of diseases associated with fibrosis.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.039 seconds)
